Does Radiofrequency Ablation Add to Chemotherapy for Unresectable Liver Metastases?

Overview

Journal Curr Colorectal Cancer Rep

Publisher Springer

Date 2012 May 22

PMID 22611343

Citations 10

Authors

Klaas M Govaert

Charlotte S van Kessel

Martijn Lolkema

Theo J M Ruers

Inne H M Borel Rinkes

Affiliations

Soon will be listed here.

Abstract

In patients with unresectable colorectal liver metastases (CRLM), radiofrequency ablation (RFA) might be a good alternative, whenever possible. In contrast to systemic therapy, the aim of RFA is to achieve complete local tumor control in an attempt to provide long-term survival. In this article we discuss the available evidence regarding the treatment of patients with unresectable CRLM, focusing on RFA in conjunction with modern systemic therapies. We observed that the available evidence in the existing literature is limited, and often consists of level 2 and 3 evidence, thereby hampering any firm conclusions. Nonetheless, RFA seems superior to chemotherapy alone in patients with liver-only disease amenable for RFA. However, the combination of RFA and chemotherapy has been demonstrated to be feasible and safe, lending support to the concept of RFA followed by chemotherapy, in order to reduce local recurrence rates and prolong survival.

Citing Articles

Progression of Femoral Osteolytic Metastases after Intramedullary Nailing and Subsequent Salvage Techniques.

Jiang W, Latich I, Lindskog D, Friedlaender G, Lee F Cancers (Basel). 2024; 16(16).

PMID: 39199585 PMC: 11352437. DOI: 10.3390/cancers16162812.

Systemic chemotherapy combined with radiofrequency ablation for colorectal cancer with liver metastasis: a retrospective cohort study.

Tran T, Nguyen H, Pham G, Thi Hoang C, Vu Q Ann Med Surg (Lond). 2023; 85(7):3334-3338.

PMID: 37427169 PMC: 10328601. DOI: 10.1097/MS9.0000000000000954.

Prognostic Factors of Radiofrequency Ablation plus Systemic Chemotherapy for Unresectable Colorectal Cancer with Liver Metastasis.

Doan K, Nguyn Vit L, Nguyen Tien T, Canh B, Ngo Thi H, Nguyen Thanh N Int J Hepatol. 2020; 2020:8836922.

PMID: 33381321 PMC: 7762673. DOI: 10.1155/2020/8836922.

The role of interventional oncology in the treatment of colorectal cancer liver metastases.

Tsitskari M, Filippiadis D, Kostantos C, Palialexis K, Zavridis P, Kelekis N Ann Gastroenterol. 2019; 32(2):147-155.

PMID: 30837787 PMC: 6394269. DOI: 10.20524/aog.2018.0338.

Laser ablation of liver tumors: An ancillary technique, or an alternative to radiofrequency and microwave?.

Sartori S, Di Vece F, Ermili F, Tombesi P World J Radiol. 2017; 9(3):91-96.

PMID: 28396723 PMC: 5368631. DOI: 10.4329/wjr.v9.i3.91.

References

Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C . Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo.... J Clin Oncol. 2007; 25(13):1670-6. DOI: 10.1200/JCO.2006.09.0928. View

Solbiati L, Goldberg S, Ierace T, Livraghi T, Meloni F, Dellanoce M . Hepatic metastases: percutaneous radio-frequency ablation with cooled-tip electrodes. Radiology. 1997; 205(2):367-73. DOI: 10.1148/radiology.205.2.9356616. View

Jakobs T, Hoffmann R, Trumm C, Reiser M, Helmberger T . Radiofrequency ablation of colorectal liver metastases: mid-term results in 68 patients. Anticancer Res. 2006; 26(1B):671-80. View

Berber E, Siperstein A . Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol. 2008; 15(10):2757-64. DOI: 10.1245/s10434-008-0043-7. View

Hecht J, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D . A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2008; 27(5):672-80. DOI: 10.1200/JCO.2008.19.8135. View

Wang J, Zhao Z, Barber B, Sherrill B, Peeters M, Wiezorek J . A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer. Br J Cancer. 2011; 104(12):1848-53. PMC: 3111208. DOI: 10.1038/bjc.2011.179. View

Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B . Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25(13):1658-64. DOI: 10.1200/JCO.2006.08.1620. View

Kattan M, Gonen M, Jarnagin W, DeMatteo R, DAngelica M, Weiser M . A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 2008; 247(2):282-7. DOI: 10.1097/SLA.0b013e31815ed67b. View

Ayav A, Germain A, Marchal F, Tierris I, Laurent V, Bazin C . Radiofrequency ablation of unresectable liver tumors: factors associated with incomplete ablation or local recurrence. Am J Surg. 2010; 200(4):435-9. DOI: 10.1016/j.amjsurg.2009.11.009. View

10.

Ruers T, Joosten J, Wiering B, Langenhoff B, Dekker H, Wobbes T . Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study. Ann Surg Oncol. 2007; 14(3):1161-9. DOI: 10.1245/s10434-006-9312-5. View

11.

Porschen R, Arkenau H, Kubicka S, Greil R, Seufferlein T, Freier W . Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol. 2007; 25(27):4217-23. DOI: 10.1200/JCO.2006.09.2684. View

12.

Abitabile P, Hartl U, Lange J, Maurer C . Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol. 2006; 33(1):67-71. DOI: 10.1016/j.ejso.2006.10.040. View

13.

Knudsen A, Kannerup A, Mortensen F, Nielsen D . Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy. Acta Radiol. 2009; 50(7):716-21. DOI: 10.1080/02841850902991634. View

14.

Scheithauer W, Rosen H, Kornek G, Sebesta C, Depisch D . Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993; 306(6880):752-5. PMC: 1677246. DOI: 10.1136/bmj.306.6880.752. View

15.

Goldberg R, Sargent D, Morton R, Fuchs C, Ramanathan R, Williamson S . A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2003; 22(1):23-30. DOI: 10.1200/JCO.2004.09.046. View

16.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

17.

Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R . Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008; 26(12):2006-12. DOI: 10.1200/JCO.2007.14.9898. View

18.

Martin 2nd R, McGuffin S, Roetzer L, Abell T, Studts J . Method of presenting oncology treatment outcomes influences patient treatment decision-making in metastatic colorectal cancer. Ann Surg Oncol. 2005; 13(1):86-95. DOI: 10.1245/ASO.2006.03.086. View

19.

Gillams A, Lees W . Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol. 2009; 19(5):1206-13. DOI: 10.1007/s00330-008-1258-5. View

20.

Sorensen S, Mortensen F, Nielsen D . Radiofrequency ablation of colorectal liver metastases: long-term survival. Acta Radiol. 2007; 48(3):253-8. DOI: 10.1080/02841850601161539. View